Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model
ConclusionsThe FXR agonist improves insulin resistance, renal lipid metabolism, and functional and structural changes in the kidney and other organs.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
More News: Bile | Carbohydrates | Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Insulin | Liver | Pancreas | Urology & Nephrology